Recent News
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day.Read Article
The pain that inflammation does not explain in SpA and PsA
Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists. This scenario reflects a dimension of these diseases that standard disease activity scores were not
Read Article
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. Glucagon-like peptide-1 receptor agonists are a class of injectable medications that mimic a gut hormone to reduce appetite, promote weight loss, and, increasingly, appear to dampen inflammation beyond their metabolic effects. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question
Read Article
"the further I look back, the further I can see the future"
Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026
@eular_org @RheumNow https://t.co/ayInzzb9lO
Aurelie Najm @AurelieRheumo ( View Tweet)
#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow https://t.co/ftx1uBP11A
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet)
📈 Do SIJ lesions progress in #axSpA?
DESIR cohort (n=649, 10yrs):
Yes, slowly, but bDMARDs reduce erosion progression
#OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
🔍 Best imaging outcome for #axSpA structural change?
SPACE cohort (n=332): MRI-SIJ fat lesions most sensitive to change
#OP0103 #EULAR2026 @RheumNow https://t.co/His1BGYmEW
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA?
COPECARE (n=25, 1yr): sCT matches ldCT with no radiation
#OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
🔍 Is #axSpA overdiagnosed locally?
IMPROVE-axSpA prosp study (n=969):
Yes!
Only 54% locally confirmed centrally
#OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
🔍Can early TNFi beat step-up csDMARDs in pSpA?
SPARTACUS RCT (n=97) says YES
60% vs 33% remission at 24 wks
#EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
💉 IXE+TZP beat IXE alone in obese PsA?
YES - TOGETHER-PsA RCT
33.5% vs 20.4% ACR50 at week 36 in 271 patients
OP069 #EULAR2026 @RheumNow
@DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
🥗 Does diet improve PsA?
DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts
Weight loss drove outcomes
OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA:
Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts
Males ⬆️rate of xray prog(msasss)
Sex diffs exist in SpA
Need for sex-specific mgt
AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v
sheila @RHEUMarampa ( View Tweet)
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet)
The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you.
Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn
Links:
Dr. John Cush @RheumNow ( View Tweet)
♂♀ Does sex matter in #axSpA long-term?
GESPIC (n=525,10y):
Yes! ♂ less symptoms but 2x more spinal progression
#OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
🔍 What defines a positive MRI for #axSpA?
SPARTAN-SSR consensus (n=1,050):
BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants
#OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
HLA-Cw6: a marker of more severe and difficult to manage psoriatic arthritis?
POS0484
#EULAR2026
@RheumNow https://t.co/MIYZxuYT4v
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Interesting pilot study using line-field confocal OCT for CLE
The “virtual biopsy” identified distinct layer-specific patterns across diff CLE subtypes including distinctions
bet ACLE & rosacea (dil. vessels, demodex mites, periannexal infil)
AbsOP099 @RheumNow #EULAR2026 https://t.co/yQSc6u4oYV
Links:
sheila @RHEUMarampa ( View Tweet)
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a disease target, synovial biopsy to guide treatment, molecular imaging to reveal subclinical disease. More tomorrow. #Rheumatology @RheumNow #EULAR2026
Antoni Chan MD (Prof) @synovialjoints ( View Tweet)
Video
From the Blog
Podcasts
EULAR 2026 Daily Podcast Day 1a
Count Your Telangiectasias (5.29.2026)-
Quiz Talk (5.22.2026)
-
Infectious Rheumatology (5.15.2026)
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
